AGEs与NO在尿毒症心血管并发症中的变化及意义  

The clinical significance and variation characteristic of AGEs and NO in cardiovascular complications in patients with uraemia

作　　者：赵华[1] 蔺勇[2] 孙国华[3] 徐学明[2] 张扬[4] 

机构地区：[1]大连市中心医院泌尿内科 [2]吉林大学第一临床医院 [3]中国人民解放军95988部队医院 [4]吉林大学药学院

出　　处：《中国实验诊断学》2006年第10期1187-1189,共3页Chinese Journal of Laboratory Diagnosis

摘　　要：目的探讨尿毒症时AGEs与NO的关系,以及AGEs与NO在尿毒症心血管并发症中的意义。方法用ELISA法检测研究对象血中AGEs的水平,用硝酸还原酶法检测研究对象血中NO含量。结果①血清AGEs水平高于健康对照组,且有心血管并发症组AGEs明显高于无心血管并发症组。②血清NO水平低于健康对照组,且有心血管并发症组NO明显低于无心血管并发症组。③AGEs与NO呈负相关。结论血中高浓度的AGEs可能通过灭活NO等机制与NO共同参与尿毒症心血管并发症的发生发展。Objective To determine the role and mechanism of advanced glycation end products（AGEs） and NO in cardiovascular complications in patients with CRF and the interaction between AGEs and NO. Methods The study population were divided into two groups. One group is a normal control and another group is a CRF group, CRF group were divided into two groups with or without cardiovascular complications. By using a competitive ELISA, we measured the AGEs levels, meanwhile, measured NO activities. Resuits （1）Compared with normal control group,the serum AGEs level with CRF group significantly increased（P 〈 0.05） ;the serum AGEs in patients with cardiovascular complications were significantly higher than in those without cardiovascular complications（ P 〈 0.05） .（2）Compared with normal control group,the serum NO activies with CRF group significantly declined（P 〈 0.05） ; the serum NO activies in patients with cardiovascular complications were significantly slower than in those without cardiovascular complications （P 〈 0.05）. （3）In patients with CRF, a significantly negative correlation was found between serum NO and AGE（ P 〈 0.05）. Condusion Those indicated that one of mechanisms of AGEs modulating cardiovascular complications is to quench NO. AGEs and NO initiate and/or exacerbate cardiovascular complications with CRF.

关 键 词：AGES NO 尿毒症 心血管并发症 

分 类 号：R692.5[医药卫生—泌尿科学]